PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia
Background. Recently, studies have been conducted all over the world to study the role of immune checkpoints in the pathogenesis of chronic lymphocytic leukemia (CLL) and the possibility of their use as prognostic markers. Of greatest interest are PD-1 (programmed cell death-1) and LAG-3 protein (ly...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-12-01
|
| Series: | Онкогематология |
| Subjects: | |
| Online Access: | https://oncohematology.abvpress.ru/ongm/article/view/876 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849409321694134272 |
|---|---|
| author | O. N. Selyutina I. B. Lysenko N. K. Guskova I. А. Novikova E. Yu. Zlatnik T. F. Pushkareva N. V. Nikolaeva I. A. Kamaeva E. A. Kapuza Ya. S. Gaysultanova L. Ya. Rozenko |
| author_facet | O. N. Selyutina I. B. Lysenko N. K. Guskova I. А. Novikova E. Yu. Zlatnik T. F. Pushkareva N. V. Nikolaeva I. A. Kamaeva E. A. Kapuza Ya. S. Gaysultanova L. Ya. Rozenko |
| author_sort | O. N. Selyutina |
| collection | DOAJ |
| description | Background. Recently, studies have been conducted all over the world to study the role of immune checkpoints in the pathogenesis of chronic lymphocytic leukemia (CLL) and the possibility of their use as prognostic markers. Of greatest interest are PD-1 (programmed cell death-1) and LAG-3 protein (lymphocyte-activation gene 3).Aim. To study the features of PD-1 (CD279) and LAG-3 (CD223) expression on blood B-cells of CLL patients and the possibility of their use as early markers for predicting the hematological response to therapy.Materials and methods. The blood of 30 patients with CLL in stage C according to Binet and 20 healthy individuals was studied by 10-color flow cytometry.Results. In patients with CLL, there were significant differences in the initial lymphocytes level, PD-1 and LAG-3 expression on B-lymphocytes, both with persons in the control group and among themselves with different hematological responses to therapy with rituximab according to the results of minimal residual disease monitoring.Conclusion. PD-1 and LAG-3 can be used as early markers for predicting the response of CLL patients to therapy. The combined use of initial lymphocytes level and PD-1 and LAG-3 expression on CD19+ blood cells has a greater prognostic value. New data obtained from the study of immune checkpoints PD-1 and LAG-3 may be useful in the development of targeted therapeutic agents. |
| format | Article |
| id | doaj-art-c9fd483985ff443b9b5c1bca686dca5f |
| institution | Kabale University |
| issn | 1818-8346 2413-4023 |
| language | Russian |
| publishDate | 2023-12-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Онкогематология |
| spelling | doaj-art-c9fd483985ff443b9b5c1bca686dca5f2025-08-20T03:35:32ZrusABV-pressОнкогематология1818-83462413-40232023-12-0118415616210.17650/1818-8346-2023-18-4-156-162720PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemiaO. N. Selyutina0I. B. Lysenko1N. K. Guskova2I. А. Novikova3E. Yu. Zlatnik4T. F. Pushkareva5N. V. Nikolaeva6I. A. Kamaeva7E. A. Kapuza8Ya. S. Gaysultanova9L. Ya. Rozenko10National Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaNational Medical Research Center of Oncology, Ministry of Health of RussiaBackground. Recently, studies have been conducted all over the world to study the role of immune checkpoints in the pathogenesis of chronic lymphocytic leukemia (CLL) and the possibility of their use as prognostic markers. Of greatest interest are PD-1 (programmed cell death-1) and LAG-3 protein (lymphocyte-activation gene 3).Aim. To study the features of PD-1 (CD279) and LAG-3 (CD223) expression on blood B-cells of CLL patients and the possibility of their use as early markers for predicting the hematological response to therapy.Materials and methods. The blood of 30 patients with CLL in stage C according to Binet and 20 healthy individuals was studied by 10-color flow cytometry.Results. In patients with CLL, there were significant differences in the initial lymphocytes level, PD-1 and LAG-3 expression on B-lymphocytes, both with persons in the control group and among themselves with different hematological responses to therapy with rituximab according to the results of minimal residual disease monitoring.Conclusion. PD-1 and LAG-3 can be used as early markers for predicting the response of CLL patients to therapy. The combined use of initial lymphocytes level and PD-1 and LAG-3 expression on CD19+ blood cells has a greater prognostic value. New data obtained from the study of immune checkpoints PD-1 and LAG-3 may be useful in the development of targeted therapeutic agents.https://oncohematology.abvpress.ru/ongm/article/view/876chronic lymphocytic leukemialag-3pd-1lymphocyte countminimal residual disease |
| spellingShingle | O. N. Selyutina I. B. Lysenko N. K. Guskova I. А. Novikova E. Yu. Zlatnik T. F. Pushkareva N. V. Nikolaeva I. A. Kamaeva E. A. Kapuza Ya. S. Gaysultanova L. Ya. Rozenko PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia Онкогематология chronic lymphocytic leukemia lag-3 pd-1 lymphocyte count minimal residual disease |
| title | PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia |
| title_full | PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia |
| title_fullStr | PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia |
| title_full_unstemmed | PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia |
| title_short | PD-1 and LAG-3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia |
| title_sort | pd 1 and lag 3 as early prognostic markers in the treatment of patients with chronic lymphocytic leukemia |
| topic | chronic lymphocytic leukemia lag-3 pd-1 lymphocyte count minimal residual disease |
| url | https://oncohematology.abvpress.ru/ongm/article/view/876 |
| work_keys_str_mv | AT onselyutina pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT iblysenko pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT nkguskova pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT ianovikova pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT eyuzlatnik pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT tfpushkareva pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT nvnikolaeva pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT iakamaeva pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT eakapuza pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT yasgaysultanova pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia AT lyarozenko pd1andlag3asearlyprognosticmarkersinthetreatmentofpatientswithchroniclymphocyticleukemia |